Taysha gene therapies reports second quarter 2021 financial results and provides corporate update

Dallas--(business wire)--taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today reported financial results for the second quarter ended june 30, 2021 and provided a corporate update. “we continue to make significant progress on several key clinical, manufacturing
TSHA Ratings Summary
TSHA Quant Ranking